DBV Technologies (NASDAQ:DBVT) Trading Down 7.1% - Should You Sell?

Key Points

• DBV Technologies shares fell 7.1% in mid-day trading to approximately $11.31, with trading volume below its average.
• Analyst sentiment remains mixed but leans positive: five analysts rate the stock a Buy, one a Hold and one a Sell, producing a consensus “Moderate Buy” rating and a $48.50 price target.
• Institutional investors own 71.74% of the company, while DBV continues developing Viaskin Peanut, an investigational patch-based treatment for peanut allergies.

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) traded down 7.1% during mid-day trading on Thursday . The company traded as low as $11.39 and last traded at $11.3110. 224,641 shares changed hands during mid-day trading, a decline of 25% from the average daily volume of 300,439 shares. The stock had previously closed at $12.17.

Analyst Ratings Changes

A number of equities research analysts have commented on DBVT shares. HC Wainwright reiterated a "buy" rating on shares of DBV Technologies in a research report on Tuesday, June 30th. Wall Street Zen downgraded shares of DBV Technologies from a "hold" rating to a "sell" rating in a research report on Saturday, July 4th. Citizens Jmp boosted their price target on shares of DBV Technologies from $47.00 to $55.00 and gave the stock a "market outperform" rating in a research report on Tuesday, June 30th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of DBV Technologies in a research note on Thursday, September 10th. Finally, Weiss Ratings cut shares of DBV Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, July 17th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $48.50.

DBV Technologies Price Performance

The company has a market cap of $725.07 million, a P/E ratio of -3.29 and a beta of -0.95. The stock has a fifty day moving average price of $13.64 and a two-hundred day moving average price of $17.00.

Institutional Trading of DBV Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vivo Capital LLC grew its position in DBV Technologies by 8.4% in the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company's stock worth $55,726,000 after acquiring an additional 205,943 shares in the last quarter. ADAR1 Capital Management LLC bought a new stake in DBV Technologies during the first quarter worth about $21,159,000. Perceptive Advisors LLC purchased a new position in shares of DBV Technologies in the 1st quarter worth about $20,146,000. Atika Capital Management LLC increased its position in shares of DBV Technologies by 31.1% during the 1st quarter. Atika Capital Management LLC now owns 271,300 shares of the company's stock valued at $5,667,000 after purchasing an additional 64,419 shares during the last quarter. Finally, Elmind Capital LP purchased a new position in shares of DBV Technologies during the 1st quarter valued at about $5,536,000. Institutional investors own 71.74% of the company's stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company's lead technology, Viaskin, is designed to deliver targeted immunotherapy through the skin without requiring an injection. Its approach is intended to expose the immune system to controlled amounts of an allergen while limiting systemic exposure.

DBV Technologies' primary product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.